Exelixis
EXEL
#1855
Rank
โ‚น1.071 T
Marketcap
โ‚น4,219
Share price
-0.51%
Change (1 day)
27.24%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น253.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น274.26. In 2023 the company made an earnings per share (EPS) of โ‚น62.00 an increase over its 2022 EPS that were of โ‚น54.09.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น253.56
2023โ‚น62.0014.61%
2022โ‚น54.09-22.97%
2021โ‚น70.23100%
2020โ‚น35.11-65.09%
2019โ‚น100.59-53.91%
2018โ‚น218.27333.96%
2017โ‚น50.30-260.61%
2016-โ‚น31.32-58.75%
2015-โ‚น75.92-42.45%
2014-โ‚น131.915.3%
2013-โ‚น125.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น1,057 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น129.06-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,360 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น195.98-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น693.75 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น328.35 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น357.58 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น348.28-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น79.72-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA